Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NIH Chronic Prostatitis Symptom Index Resource Report Resource Website |
NIH Chronic Prostatitis Symptom Index (RRID:SCR_001482) | CPSI, NIH-CPSI | assessment test provider, material resource | Questionnaire developed by physicians in NIDDK's Chronic Prostatitis Collaborative Research Network that can help physicians to accurately measure the severity of prostatitis symptoms and their impact on a patient's lifestyle. The CPSI questionnaire assesses pain, urination, and the effect of chronic prostatitis on daily activities. With this information, researchers and physicians can reliably evaluate whether potential treatments are working. The questionnaire was originally published in the Journal of Urology in August 1999 (Vol. 162, pages 369-375). It is available as a PDF document in English, Spanish, German and Korean. | pain, symptom, quality of life, male | is listed by: NIDDK Information Network (dkNET) | Prostatitis | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152732 | SCR_001482 | Chronic Prostatitis Symptom Index, National Institutes of Health Chronic Prostatitis Symptoms Index | 2026-07-25 12:12:21 | 0 | |||||
|
Biospecimens/Biorepositories: Rare Disease-HUB (RD-HUB) Resource Report Resource Website |
Biospecimens/Biorepositories: Rare Disease-HUB (RD-HUB) (RRID:SCR_004327) | RD-HUB | biomaterial supply resource, material resource | A database of biospecimens collected, stored, and distributed by biorepositories in the United States and around the globe. Its goals are: To help and assist interested parties and investigators search, locate, and identify desired biospecimens needed for their research; to facilitate collaboration and sharing of material and data among investigators across the globe; to accelerate research to facilitate the discovery of new treatments, therapeutics and eventually cures for rare diseases as well as common diseases; to identify, locate and increase the awareness of existing biorepositories across the globe; and to link the RD-HUB with the Global Rare Diseases Patient Registry and Data Repository (GRDR). | rare disease, disease, public |
lists: NIDDK Central Repository lists: National Disease Research Interchange is listed by: NIH Data Sharing Repositories is listed by: One Mind Biospecimen Bank Listing is listed by: Accelerated Cure Project MS Repository is listed by: Cooperative Human Tissue Network Western Division at Vanderbilt University Medical Center is listed by: NIDDK Information Network (dkNET) is related to: GRDR has parent organization: Office of Rare Diseases Research |
Rare disease, Aging | NIH | PMID:20609392 | Public, The community can contribute to this resource | nlx_143682 | http://biospecimens.ordr.info.nih.gov/ | SCR_004327 | Biospecimens / Biorepositories: Rare Disease-HUB, Biospecimens/Biorepositories: Rare Disease-HUB, Rare Disease-HUB | 2026-07-25 12:12:30 | 0 | |||
|
Mammalian Gene Collection Resource Report Resource Website 10+ mentions |
Mammalian Gene Collection (RRID:SCR_007024) | MGC | cell repository, biomaterial supply resource, material resource | NIH initiative project to provide full-length open reading frame (FL-ORF) clones for human, mouse, and rat genes, cow. MGC cDNA clones were obtained by screening of cDNA libraries, by transcript-specific RT-PCR cloning, and by DNA synthesis of cDNA inserts. All MGC sequences are deposited in GenBank and clones can be purchased from distributors of IMAGE consortium. With conclusion of MGC project in March 2009, GenBank records of MGC sequences will be frozen, without further updates. Since definition of what constitutes full-length coding region for some of genes and transcripts for which they have MGC clones will likely change in future, users planning to order MGC clones will need to monitor for these changes. Users can make use of genome browsers and gene-specific databases, such as the UCSC Genome browser, NCBI's Map Viewer, and Entrez Gene, to view relevant regions of genome (browsers) or gene-related information (Entrez Gene). | cell line, cdna, frozen, clone, vector, gene, open reading frame, sequence, expressed sequence tag, bio.tools, FASEB list |
is listed by: One Mind Biospecimen Bank Listing is listed by: bio.tools is listed by: Debian is related to: One Mind Biospecimen Bank Listing is related to: NIDDK Information Network (dkNET) is related to: ATCC is related to: GenBank is related to: Invitrogen Clones is related to: Open Biosystems is related to: Zebrafish Gene Collection has parent organization: National Cancer Institute |
NIH Blueprint for Neuroscience Research | Free, Freely available | biotools:mammalian_gene_collection, nif-0000-00195 | https://bio.tools/mammalian_gene_collection | SCR_007024 | Mammalian Gene Collection | 2026-07-27 09:32:43 | 46 | |||||
|
University of Pennsylvania Center for Molecular Studies in Digestive and Liver Diseases Cell Culture Core Resource Report Resource Website |
University of Pennsylvania Center for Molecular Studies in Digestive and Liver Diseases Cell Culture Core (RRID:SCR_015621) | cell repository, biomaterial supply resource, material resource | Core facility that maintains a centralized repository of cells and reagents pertinent to digestive, liver and pancreatic disease research. It also provides training for labs in new cell culture (2D and 3D) techniques. | digestive disease, liver disease, pancreatic disease, cell repository, reagent, cell culture |
is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pennsylvania Center for Molecular Studies in Digestive and Liver Diseases is organization facet of: University of Pennsylvania Center for Molecular Studies in Digestive and Liver Diseases |
digestive disease, liver disease, pancreatic disease | NIDDK P30 DK050306 | Available to the research community | SCR_015621 | 2026-07-27 09:35:01 | 0 | ||||||||
|
UCSF Liver Center Cell Biology Core Resource Report Resource Website |
UCSF Liver Center Cell Biology Core (RRID:SCR_015600) | cell repository, biomaterial supply resource, material resource | Core whose purpose is providing primary and immortalized liver cells for experimental use as well as other material such as human liver cells, primary hepatocytes, and immortalized cell lines. | cell biology, cell lines, liver cells, hypatocyte |
is listed by: NIDDK Information Network (dkNET) has parent organization: UCSF Liver Center is organization facet of: UCSF Liver Center |
liver disease | NIDDK P30 DK026743 | Available to the research community | SCR_015600 | 2026-07-27 09:35:00 | 0 | ||||||||
|
University of Chicago Digestive Diseases Research Core Center Integrated Translational Research Core Resource Report Resource Website |
University of Chicago Digestive Diseases Research Core Center Integrated Translational Research Core (RRID:SCR_015606) | cell repository, biomaterial supply resource, material resource | Core that serves as both a central repository for all the samples and data shared by the other cores and a catalyst for interdisciplinary research. | integrated translational research, communication, digestive disease research |
is listed by: NIDDK Information Network (dkNET) has parent organization: University of Chicago Digestive Diseases Research Core Center is organization facet of: University of Chicago Digestive Diseases Research Core Center |
digestive disease | NIDDK P30 DK042086 | Available to the research community | SCR_015606 | 2026-07-27 09:35:09 | 0 | ||||||||
|
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease Resource Report Resource Website 1+ mentions |
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (RRID:SCR_000690) | CRISP | clinical trial, resource | A five-year prospective cohort study following 240 patients who have autosomal-dominant polycystic kidney disease (PKD) to determine whether changes in anatomic characteristics of their kidneys as measured by magnetic resonance imaging will be useful in providing surrogate measures for disease progression. CRISP's overall goal is to develop methods that would facilitate shortening the observation period necessary to determine efficacy of treatment interventions in PKD patients. Specific goals of this study are to: * Quantify cyst growth and ascertain severity of renal parenchymal involvement by sequential measurement of total kidney volume and the ratio of intact parenchyma to renal parenchyma occupied by cysts over time * Establish useful clinical correlations of imaging data with other markers of disease progression * Identify and test other potential markers or indices of disease progression, for example, assessment of loss of heterozygosity of renal cells shed in the urine, or other markers, in cohorts of patients with PKD * Gain information about the cost-effectiveness, patient acceptability, and advantages and disadvantages of different imaging techniques used serially in patients with PKD. Some experience has been gained in establishing that repeat imaging of the same PKD patient, using these techniques, yields reproducible estimates of kidney size and the proportion of renal parenchyma occupied by cysts. MRI may also have the advantage of permitting simultaneous estimation of GFR. Ultrasound has the advantage of being more cost-effective and perhaps more acceptable to patients for repetitive studies, but the measurements may be less accurate and reproducible. Nonetheless, there is very limited experience in applying these techniques to follow progression of the renal disease. Development of improved, reproducible imaging methods that assess cyst growth and provide markers of disease progression could markedly improve the feasibility of clinical trials. Participating clinical centers are Emory University, the Mayo Clinic, University of Kansas, and the University of Alabama at Birmingham. The data coordinating and imaging analysis center is at Washington University. (PI has since moved to University of Pittsburgh) The study found that kidney enlargement resulting from the expansion of cysts is continuous, quantifiable, and associated with the decline of renal function. Cystic expansion occurs at a consistent rate per individual, although it is heterogeneous in the population, and that larger kidneys are associated with more rapid decrease in renal function. These anatomic characteristics of patient kidneys may provide useful surrogate measures for disease progression, and hence enhance the development of targeted therapies for autosomal dominant PKD. CRISP III is a five-year prospective cohort study to follow ~170 remaining autosomal dominant polycystic kidney disease (ADPKD) patients who were part of the original CRISP cohort study. CRISP III will verify and extend the preliminary observations of CRISP to determine the extent to which quantitative (kidney volume and blood flow, and hepatic and kidney cyst volume) or qualitative (cyst distribution and character) structural parameters predict renal insufficiency and develop and test new metrics to quantify and monitor disease progression. Urine metabolites and the genome will be correlated with the progression of disease to look for new, predictive disease biomarkers. This information from CRISP III will help determine if the kidney enlargement, blood flow, cyst distribution, or urine metabolites can function as an informative surrogate measure for disease progression. | mri, kidney volume, cyst volume, kidney, renal function, disease progression, measure, blood flow, hepatic cyst volume, kidney cyst volume, renal insufficiency, urine metabolite, surrogate measure, clinical, intervention |
is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pittsburgh; Pennsylvania; USA |
Polycystic kidney disease, Autosomal dominant polycystic kidney disease | NIDDK 5U01DK056961 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152795 | SCR_000690 | Consortium of Radiologic Imaging Study of PKD | 2026-07-27 09:31:01 | 3 | |||||
|
Look AHEAD Resource Report Resource Website 10+ mentions |
Look AHEAD (RRID:SCR_001490) | Look AHEAD | clinical trial, resource | 16-center, randomized clinical trial investigating the long-term health consequences of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity in overweight volunteers with type 2 diabetes. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. Participants will be followed for a total of 11 to 13.5 years from randomization. The primary hypothesis is that the incidence rate of the first post-randomization occurrence of a composite outcome, which includes * cardiovascular death (including fatal myocardial infarction and stroke), * non-fatal myocardial infarction, * hospitalized angina, and * non-fatal stroke, over a planned follow-up period of up to 13.5 years will be reduced among participants assigned to the Lifestyle Intervention compared to those assigned to the control condition, Diabetes Support and Education. Look AHEAD will also test for reductions in the incidence of three secondary composite outcomes and examine the effect of the intervention on cardiovascular disease risk factors, diabetes control and complications, general health, and quality of life, and psychological outcomes. The cost and cost-effectiveness of the Lifestyle Intervention relative to Diabetes Support and Education will be assessed. The Look AHEAD intensive lifestyle intervention ended September, 2012. Participants continue to be followed to determine the long-term effects of the intervention on health outcomes. | weight loss, caloric intake, physical activity, health outcome, long-term effect, longitudinal, intervention, late adult human, middle adult human, cardiovascular disease, risk factor, diabetes control, diabetes complication, health, quality of life, psychological outcome, clinical |
is listed by: NIDDK Information Network (dkNET) has parent organization: Wake Forest University; North Carolina; USA |
Type 2 diabetes, Overweight, Control | NIDDK U01DK057136 | Restricted | nlx_152745 | https://www.lookaheadtrial.org/public/home.cfm | SCR_001490 | Action for Health in Diabetes, Look AHEAD - Action for Health in Diabetes | 2026-07-27 09:31:13 | 46 | ||||
|
Frequent Hemodialysis Network Daily Trial Resource Report Resource Website |
Frequent Hemodialysis Network Daily Trial (RRID:SCR_001527) | FHN Daily Trial | clinical trial, resource | Randomized controlled clinical trial to understand how increasing hemodialysis to six times a week from the standard of three times a week may result in improved heart health. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialyis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale. In addition, main secondary outcomes have been designated for each of seven outcome domains: 1) cardiovascular structure and function (change in LV mass), 2) health-related quality of life/physical function (change in the PHC), 3) depression/burden of illness (change in Beck Depression Inventory), 4) nutrition (change in serum albumin), 5) cognitive function (change in the Trail Making Test B), 6) mineral metabolism (change in average predialysis serum phosphorus), and 7) clinical events (rate of non-access hospitalization or death). Hypertension and anemia are also main outcome domains, but without designation of single first priority outcomes. | hemodialysis, cardiovascular, kidney, heart |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is related to: Frequent Hemodialysis Network Nocturnal Trial has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Hemodialysis, End Stage Renal Disease | NIDDK | PMID:21091062 PMID:17164834 PMID:17699439 |
Free, Freely available | nlx_152828 | https://www.niddk.nih.gov/news/for-reporters/frequent-hemodialysis-network-daily-trial/Pages/default.aspx | SCR_001527 | Frequent Hemodialysis Network (FHN) Daily Trial | 2026-07-27 09:31:14 | 0 | |||
|
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C Resource Report Resource Website |
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (RRID:SCR_001553) | Virahep-C | clinical trial, resource | Study designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied. All patients were treated with combination therapy of pegylated interferon and ribavirin for 48 weeks, and were followed for an additional 48 week safter cessation of therapy. 400 patients, half African-American and half Caucasian American, from 8 clinical centers with the goals of establishing rates of response to optimal current therapy in the two ethnic groups, identify factors predictive of response, establish patterns of viral kinetics in response to antiviral therapy, and test hypotheses concerning viral and host factors determining response to therapy. Four ancillary studies designed to elucidate biological and virological basis for non-response are also included in Virahep-C. Additionally, the study has central facilitates for pathology, the virological testing laboratory and a serum/tissue repository. | african-american, pegylated interferon, drug, ribavirin, caucasian-american, chronic hepatitis c genotype 1, biomaterial supply resource, efficacy, treatment, adult human, male, female, interferon, resistance, antiviral therapy, serum, tissue |
is listed by: One Mind Biospecimen Bank Listing is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: University of Pittsburgh; Pennsylvania; USA |
Chronic hepatitis C, Hepatitis C virus | NIDDK U01DK60329 | Free, Freely available | nlx_152861 | http://www.edc.gsph.pitt.edu/virahepc/, http://www.virahepc.org/ | SCR_001553 | Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C), Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C | 2026-07-27 09:31:14 | 0 | ||||
|
TINSAL-T2D Resource Report Resource Website 1+ mentions |
TINSAL-T2D (RRID:SCR_001546) | TINSAL-T2D, TINSAL-T2D-II | clinical trial, resource | Nationwide, randomized, double blind, multi-center research study to determine whether the drug salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study is conducted in two stages. The primary objective of the first stage is to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk. | salsalate, drug, intervention, treatment, hba1c, inflammation, obesity, metabolic syndrome, adult human, male, female, non-steroidal anti-inflammatory drug, diabetes management, placebo, glycemic control |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: Joslin Diabetes Center |
Type 2 diabetes, Inflammation, Metabolic syndrome, Cardiac disease, Obesity | NIDDK 5R01DK095327 | PMID:20231565 PMID:17959861 |
Free, Freely available | nlx_152855 | https://clinicaltrials.gov/ct2/show/NCT00392678 | http://www.tinsal-t2d.org/ | SCR_001546 | Targeting Inflammation Using Salsalate for Type 2 Diabetes-stage II, Targeting INflammation using SALsalate for Type 2 Diabetes | 2026-07-27 09:31:14 | 1 | ||
|
Study of Nutrition in Acute Pancreatitis Resource Report Resource Website |
Study of Nutrition in Acute Pancreatitis (RRID:SCR_001544) | SNAP | clinical trial, resource | Randomized multi-center clinical trial designed to test whether duodenojejunal (DJ) feeding is more effective than nasogastric (NG) feeding in providing enteral nutrition to patients with severe acute pancreatitis. SNAP will enroll participants with severe acute pancreatitis admitted to the intensive care unit at eight clinical centers. Upon enrollment, participants are assigned to NG or DJ feeding and managed for up to 28 days or until weaned on to solid food. Follow-up continues until participants are discharged from the hospital or for a maximum of 60 days. Outcomes relate to feeding tolerance and failure, nutritional status, risk for life-threatening pancreatic/systemic complications, and hospital mortality. | duodenojejunal feeding, naso gastric feeding, enteral nutrition, feeding tolerance, outcome, acute pancreatitis, distal jejunal feeding, intervention, nutrition, treatment, adult human, male, female, pancreas |
is listed by: ClinicalTrials.gov is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pittsburgh; Pennsylvania; USA |
Pancreatitis | NIDDK | Free, Freely available | nlx_152854 | SCR_001544 | 2026-07-27 09:31:14 | 0 | ||||||
|
Renin Angiotensin System Study Resource Report Resource Website 1+ mentions |
Renin Angiotensin System Study (RRID:SCR_013385) | RASS/B-RASS, RASS | clinical trial, resource | Randomized, multicenter, double-blind study to determine if renin angiotensin medications, either losartan (angiotensin II blocker) or enalapril (converting enzyme inhibitor), can prevent or delay the onset of diabetic kidney disease in patients with type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria. Two hundred eight five patients ages 16-61 with 2-20 yrs of Type 1 Diabetes Mellitus and no renal functional abnormalities were randomized into a parallel, double-blind, placebo-controlled study involving 3 groups (95 patients/group). Each group received an angiotensin-converting enzyme inhibitor (ACEI) (enalapril), or an angiotensin II receptor blocker (Losartan), or placebo. All patients had their usual Diabetes Mellitus (DM) management. Baseline studies included measures of glomerular filtration rate (GFR), urinary albumin excretion rate (UAE), blood pressure (BP), and a percutaneous renal biopsy. Patients were followed by quarterly measures of BP, HbA1C, UAE, and drug compliance. There were annual measures of GFR and a repeat renal biopsy after 5 yrs in the study. The main endpoint is kidney structural changes over time, especially mesangial fractional volume (v(Mes/glom)). Secondary endpoints will be other DN structural measures and measures of kidney function (UAE, GFR). These studies will determine whether rennin angiotensin system blockage in the early stages of DN can prevent the early kidney structural changes in this important disorder. Ancillary studies will evaluate the effects of treatment group on the development and progression of diabetic retinopathy and will develop predictors of study participants'''' compliance. Baseline, 2.5 and 5 year retinal fundus photographs in the RASS patients were obtained. | enalapril, drug, losartan, angiotensin, medication, kidney, intervention, clinical, adolescent, adult human, renal biopsy, renin-angiotensin system, diabetic nephropathy, kidney, placebo, glomerular filtration rate, urinary albumin excretion rate, blood pressure |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Minnesota Twin Cities; Minnesota; USA |
Type 1 diabetes, Diabetic kidney disease, Retinopathy, Nephropathy, Diabetes | NIDDK | PMID:19571282 | nlx_152849 | SCR_013385 | Renin Angiotensin System Blockage-DN (RASS), Renin Angiotensin System Study (RASS/B-RASS) | 2026-07-27 09:34:24 | 1 | |||||
|
NIH Data Sharing Repositories Resource Report Resource Website 1+ mentions |
NIH Data Sharing Repositories (RRID:SCR_003551) | NIH Data Sharing Repositories | data or information resource, data set | A listing of NIH supported data sharing repositories that make data accessible for reuse. Most accept submissions of appropriate data from NIH-funded investigators (and others), but some restrict data submission to only those researchers involved in a specific research network. Also included are resources that aggregate information about biomedical data and information sharing systems. The table can be sorted according by name and by NIH Institute or Center and may be searched using keywords so that you can find repositories more relevant to your data. Links are provided to information about submitting data to and accessing data from the listed repositories. Additional information about the repositories and points-of-contact for further information or inquiries can be found on the websites of the individual repositories. | data repository |
lists: NIDDK Information Network (dkNET) lists: Nuclear Receptor Signaling Atlas lists: Biospecimens/Biorepositories: Rare Disease-HUB (RD-HUB) lists: Eukaryotic Pathogen Database Resources lists: Immune Epitope Database and Analysis Resource (IEDB) lists: LONI Image and Data Archive lists: BEI Resource Repository lists: Nanomaterial Registry lists: Metabolomics Workbench lists: National Database for Clinical Trials related to Mental Illness lists: RDoCdb lists: Database of Interacting Proteins (DIP) lists: NIH MRI Study of Normal Brain Development lists: PubChem lists: 1000 Functional Connectomes Project lists: Parkinson's Progression Markers Initiative lists: Mouse Genome Informatics (MGI) lists: Federal Interagency Traumatic Brain Injury Research Informatics System lists: NIH Human Connectome Project lists: Biological General Repository for Interaction Datasets (BioGRID) lists: Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) lists: Nanomaterial Registry is related to: NIH MRI Study of Normal Brain Development is related to: Eukaryotic Pathogen Database Resources is related to: Parkinson's Progression Markers Initiative is related to: Federal Interagency Traumatic Brain Injury Research Informatics System is related to: NIH Human Connectome Project is related to: National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) is related to: Cancer Imaging Archive (TCIA) is related to: Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) is related to: NIDDK Information Network (dkNET) is related to: UniProt is related to: GeneNetwork is related to: Zebrafish Information Network (ZFIN) is related to: WormBase is related to: Database of Interacting Proteins (DIP) is related to: iDASH is related to: PubChem is related to: CardioVascular Research Grid (CVRG) is related to: 1000 Functional Connectomes Project is related to: Mouse Genome Informatics (MGI) is related to: FlyBase is related to: PeptideAtlas is related to: Biological General Repository for Interaction Datasets (BioGRID) is related to: GRDR is related to: National Institute on Drug Abuse Center for Genetic Studies is related to: BEI Resource Repository has parent organization: National Library of Medicine |
NIH | nlx_157683 | SCR_003551 | 2026-07-27 09:31:47 | 4 | ||||||||
|
Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C Resource Report Resource Website |
Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C (RRID:SCR_006787) | PEDS-C | clinical trial, resource | Multi-center, randomized controlled trial that studied peginterferon therapy, with or without ribavirin, in children with chronic hepatitis C. Approximately 120 children were randomly assigned to receive peginterferon alfa-2a alone or peginterferon with ribavirin for 48 weeks. Samples of blood, genomic DNA, and liver tissue are stored in the NIDDKrepositories. A long-term follow up study of the clinical trial participants is underway. | child, young human, peginterferon alfa-2a, ribavirin, drug, male, female, adolescent, pediatric |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) is related to: NIDDK Central Repository has parent organization: ClinicalTrials.gov |
Chronic hepatitis C viral infection, Hepatitis C virus | NIDDK | PMID:18042575 | nlx_152846 | http://www.pedsc.org | SCR_006787 | Pegylated Interferon +/- Ribavirin for Children With Hepatitis C, Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C (Peds-C) | 2026-07-27 09:32:39 | 0 | ||||
|
Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction Resource Report Resource Website |
Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (RRID:SCR_006897) | EPISOD | clinical trial, resource | A prospective, double-blind, randomized, sham-controlled, multi-center clinical trial that enrolls subjects who have received a prior cholecystectomy and are diagnosed with the clinical syndrome of Sphincter of Oddi Dysfunction III (SOD III) as defined by the Rome III criteria. The goal of the study is to asses the value of endoscopic sphincterotomy as a treatment for adult subjects categorized as SOD III suffering from pain after cholecystectomy and to define the role of manometry in treating these patients. | clinical, treatment, intervention, sphincterotomy, pancreatic, pancreas, pancreatitis, biliary, adult human, male, female, manometry |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
Cholecystectomy, Sphincter of Oddi Dysfunction | NIDDK | nlx_152824 | http://www.episod.org/ | SCR_006897 | Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction, Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction (EPISOD) | 2026-07-27 09:32:40 | 0 | |||||
|
Complementary and Alternative Medicine for Urological Symptoms Resource Report Resource Website |
Complementary and Alternative Medicine for Urological Symptoms (RRID:SCR_007131) | CAMUS | clinical trial, resource | Randomized, multicenter, double blind, placebo controlled clinical trial of phytotherapy for benign prostate symptoms among men. The CAMUS trial will test Saw palmetto in about 369 men. Men who decide to be part of the CAMUS trial will be given one out of two possible treatments at random. One out of every two men would get an inactive placebo treatment. One out of every two men would get Saw palmetto pills. This kind of scientific study is the best way to find out if the plant extracts really work to prevent men with benign prostatic hyperplasia (BPH) from getting worse. During the study, men will not know which of the two treatments they are assigned to. They will be followed very closely by a study team every 12 weeks to see how they are doing. Men in the CAMUS trial will be studied over 72 weeks. Ten clinical centers will participate in the trial. They are located at: Columbia University, NY, NY; New York University, NY, NY; University of Texas Southwestern Medical Center, Dallas, Texas; University of Colorado, Denver, CO; Washington University, St. Louis, MO; Yale University, New Haven, CT; Queens University, Hamilton, Ontario, Canada; Northwestern University, Chicago, IL; University of Maryland, Baltimore, MD; University of California at San Francisco, San Francisco, CA. | phytotherapy, prostate, benign, treatment, male, adult human, saw palmetto, placebo, herbal therapy, middle adult human, late adult human, urology |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: University of Alabama at Birmingham; Alabama; USA |
Benign prostatic hyperplasia | NCCAM ; NIDDK ; Office of Dietary Supplements ; NIDDK U01DK63795; NIDDK U01DK63797; NIDDK U01DK63825; NIDDK U01DK63835; NIDDK U01DK63866; NIDDK U01DK63833; NIDDK U01DK63862; NIDDK U01DK63840; NIDDK U01DK63883; NIDDK U01DK63831; NIDDK U01DK63778; NIDDK U01DK63788 |
PMID:21954478 PMID:21741692 PMID:21497839 |
nlx_152791 | http://www.camus.uab.edu/camus/html/index.htm |
SCR_007131 | Complementary and Alternative Medicine for Urological Symptoms Clinical Trial, Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Clinical Trial, Complementary and Alternative Medicine for Urological Symptoms (CAMUS) | 2026-07-27 09:32:44 | 0 | ||||
|
Focal Segmental Glomerulosclerosis in Children and Young Adults Interventional Study Resource Report Resource Website |
Focal Segmental Glomerulosclerosis in Children and Young Adults Interventional Study (RRID:SCR_007130) | FSGS in Children and Young Adults Interventional Study | clinical trial, resource | Network of collaborative research centers that tested the effects of treatment with cyclosporine to treatment with mycophenalate mofetil combined with oral pulse dexamethasone in children and young adults with focal segemental glomerulosclerosis. Efficacy was assessed in terms of induction of remission of proteinuria after 52 weeks of treatment and sustained remission after 26 weeks off treatment. The clinical sites were State University of New York, Stony Brook; Montefiore Medical Center; Seattle Children''''s Medical Center; Medical City Dallas Hospital; and the University of North Carolina. The Cleveland Clinic is the data-coordinating center, and NephCure will fund ancillary studies. | child, early adult, young human, proteinuria, kidney disease, intervention, prednisone, cyclosporine, mycophenalate mofetil, dexamethasone, cyclosporine-a, male, female |
is listed by: ClinicalTrials.gov is affiliated with: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Focal Segmental Glomerulosclerosis, Focal Segmental Glomerulosclerosis Nephrotic Syndrome | NIDDK | nlx_152826 | http://www.fsgstrial.org | SCR_007130 | Focal Segmental Glomerulosclerosis Clinical Trial, Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT), Focal Segmental Glomerulosclerosis (FSGS) Clinical Trial, Focal Segmental Glomerulosclerosis (FSGS) in Children and Young Adults Interventional Study | 2026-07-27 09:32:44 | 0 | |||||
|
Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia Resource Report Resource Website |
Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia (RRID:SCR_007126) | MIST for BPH | clinical trial, resource | Randomized clinical trial to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. The study has been terminated. (Inability to recruit required sample size.) | transurethral microwave thermotherapy, transurethral needle ablation, therapy, drug, finasteride, alfuzosin, treatment, clinical, intervention, male, middle adult human, late adult human, prostate |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Benign Prostatic Hyperplasia | NIDDK | nlx_152844 | SCR_007126 | Minimally Invasive Surgical Therapies (MIST) Treatment Consortium for Benign Prostatic Hyperplasia (BPH), Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia | 2026-07-27 09:32:45 | 0 | ||||||
|
Chronic Prostatitis Collaborative Research Network Clinical Trial- Alfuzosin Resource Report Resource Website |
Chronic Prostatitis Collaborative Research Network Clinical Trial- Alfuzosin (RRID:SCR_015886) | data or information resource, data set | Clinical trial by the Chronic Prostatitis Collaborative Research Network (CPCRN chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)) that was established to conduct randomized clinical trials of promising therapies for this syndrome. In response to the findings of previous trials, the CPCRN conducted a multicenter, randomized, placebo-controlled trial of alfuzosin to determine whether the symptoms CP/CPPS could be reduced in men who had recently received a diagnosis of CP/CPPS and who had not previously been treated with this class of drug. | chronic, prostatitis, alfuzosin, collaborative research, clinical trial, clinical study |
is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers |
Chronic Prostatitis | Available upon request, Public, Free | https://www.clinicaltrials.gov/show/NCT00371033 | SCR_015886 | Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) (CPCRN RCT#2) | 2026-07-27 09:35:06 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the T1D Resources search. From here you can search through a compilation of resources used by T1D and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that T1D has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on T1D then you can log in from here to get additional features in T1D such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into T1D you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
